ATLANTA, April 24, 2024 (GLOBE NEWSWIRE) -- Sharecare (Nasdaq: SHCR), the digital health company that helps people manage all their health in one place, today announced that it will report first quarter fiscal 2024 financial results on Thursday, May 9, 2024, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. EDT on the same day.
Conference Call Details
The conference call can be accessed by dialing (833) 636-1352 for U.S. participants, or (412) 902-4148 for international participants, and asking to be joined into the Sharecare call; or via live audio webcast, available online at https://investors.sharecare.com.
A webcast replay of the call will be available for on-demand listening at the same link and will remain available for approximately 90 days.
About Sharecare
Sharecare is the leading digital health company that helps people – no matter where they are in their health journey – unify and manage all their health in one place. Our comprehensive and data-driven virtual health platform is designed to help people, providers, employers, health plans, government organizations, and communities optimize individual and population-wide well-being by driving positive behavior change. Driven by our philosophy that we are all together better, at Sharecare, we are committed to supporting each individual through the lens of their personal health and making high-quality care more accessible and affordable for everyone. To learn more, visit www.sharecare.com.
Media Relations: This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations: This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$1.43 |
Daily Volume: | 0 |
Market Cap: | US$531.790M |
September 10, 2024 August 09, 2024 March 28, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB